resveratrol has been researched along with Lipid Metabolism, Inborn Error in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laforêt, P; Løkken, N; Madsen, KL; Nadaj-Pakleza, A; Storgaard, JH; Tard, C; van Hall, G; Vissing, J; Voermans, NC; Ørngreen, MC | 1 |
| Baartscheer, A; Bezzina, CR; Bleeker, JC; Coronel, R; Ferdinandusse, S; Guan, K; Houtkooper, RH; IJlst, L; Knottnerus, SJG; Li, W; Luo, X; Mengarelli, I; Portero, VM; Ulbricht, Y; Verkerk, AO; Visser, G; Wanders, RJA; Wijburg, FA; Wüst, RCI | 1 |
1 trial(s) available for resveratrol and Lipid Metabolism, Inborn Error
| Article | Year |
|---|---|
No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Carnitine O-Palmitoyltransferase; Congenital Bone Marrow Failure Syndromes; Cross-Over Studies; Exercise Tolerance; Fatty Acids; Humans; Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Mitochondrial Diseases; Muscular Diseases; Oxidation-Reduction; Resveratrol | 2022 |
1 other study(ies) available for resveratrol and Lipid Metabolism, Inborn Error
| Article | Year |
|---|---|
Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Can Be Improved by Lowering Accumulation of Fatty Acid Oxidation Intermediates.
Topics: Action Potentials; Acyl-CoA Dehydrogenase, Long-Chain; Arrhythmias, Cardiac; Cardiac Electrophysiology; Congenital Bone Marrow Failure Syndromes; Epoxy Compounds; Fatty Acids; Humans; Induced Pluripotent Stem Cells; Lipid Metabolism, Inborn Errors; Mitochondria; Mitochondrial Diseases; Muscular Diseases; Myocytes, Cardiac; Oxidation-Reduction; Resveratrol | 2020 |